Is there a future for tigecycline?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Multidrug resistantCurrent research in microbial sciences · 2025
   Review
2. Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation.Antibiotics (Basel, Switzerland) · 2023
   Article
3. Safety and effectiveness of tigecycline combination therapy in renal transplant patients with infection due to carbapenem-resistant gram-negative bacteria.Frontiers in cellular and infection microbiology · 2023
   Article
4. Efficacy and Safety of Colistin versus Tigecycline for Multi-Drug-Resistant and Extensively Drug-Resistant Gram-Negative Pathogens-A Meta-Analysis.Antibiotics (Basel, Switzerland) · 2022
   Article
5. Virulence Characteristics and Emerging Therapies for Biofilm-FormingBiology · 2022
   Review
6. Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.Antimicrobial agents and chemotherapy · 2021
   Article
7. Tigecycline Therapy for Multi-drug-ResistantSN comprehensive clinical medicine · 2020
   Article
8. The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug ResistantMicroorganisms · 2019
   Review
9. The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How.Frontiers in public health · 2019
   Review
10. What's new in multidrug-resistant pathogens in the ICU?Annals of intensive care · 2016
    Review
11. [Safety of 48 cases of infection after allogeneic stem cell transplantation treated with tigecycline].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015
    Article

Corrections and comments

• Comment on
  Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.2014

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as